JP2016534717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534717A5 JP2016534717A5 JP2016524494A JP2016524494A JP2016534717A5 JP 2016534717 A5 JP2016534717 A5 JP 2016534717A5 JP 2016524494 A JP2016524494 A JP 2016524494A JP 2016524494 A JP2016524494 A JP 2016524494A JP 2016534717 A5 JP2016534717 A5 JP 2016534717A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- chimeric receptor
- cell
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700010039 chimeric receptor Proteins 0.000 claims 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims 11
- 210000000822 natural killer cell Anatomy 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 230000000735 allogeneic effect Effects 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000004520 electroporation Methods 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 108020001756 ligand binding domains Proteins 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000010361 transduction Methods 0.000 claims 2
- 230000026683 transduction Effects 0.000 claims 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 108010047620 Phytohemagglutinins Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001885 phytohemagglutinin Effects 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892218P | 2013-10-17 | 2013-10-17 | |
| US61/892,218 | 2013-10-17 | ||
| US201462026243P | 2014-07-18 | 2014-07-18 | |
| US62/026,243 | 2014-07-18 | ||
| PCT/US2014/060999 WO2015058018A1 (en) | 2013-10-17 | 2014-10-17 | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534717A JP2016534717A (ja) | 2016-11-10 |
| JP2016534717A5 true JP2016534717A5 (enExample) | 2017-11-24 |
| JP6417413B2 JP6417413B2 (ja) | 2018-11-07 |
Family
ID=52828713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524494A Active JP6417413B2 (ja) | 2013-10-17 | 2014-10-17 | 多様な腫瘍に対する抗体依存性細胞毒性を誘発するキメラ受容体 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3057986B1 (enExample) |
| JP (1) | JP6417413B2 (enExample) |
| KR (1) | KR102308597B1 (enExample) |
| CN (1) | CN105683214B (enExample) |
| AU (1) | AU2014337195B2 (enExample) |
| BR (1) | BR112016007695A2 (enExample) |
| CA (1) | CA2926267C (enExample) |
| IL (1) | IL245088A0 (enExample) |
| SG (1) | SG11201602979RA (enExample) |
| WO (1) | WO2015058018A1 (enExample) |
| ZA (1) | ZA201602798B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| MX2017003062A (es) * | 2014-09-09 | 2017-12-14 | Unum Therapeutics | Receptores quimericos y usos de los mismos en terapia inmune. |
| DE112016002056T5 (de) | 2015-05-06 | 2018-02-08 | Snipr Technologies Limited | Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen |
| WO2017061615A1 (ja) * | 2015-10-08 | 2017-04-13 | 国立大学法人名古屋大学 | キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法 |
| EP3362075B1 (en) * | 2015-10-15 | 2023-06-07 | Celularity Inc. | Natural killer cells and ilc3 cells and uses thereof |
| GB201602974D0 (en) * | 2016-02-19 | 2016-04-06 | Clube Jasper R | Engineered cells & methods (1) |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| US20190284298A1 (en) * | 2016-07-19 | 2019-09-19 | Unum Therapeutics Inc. | Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatment |
| EP3315511A1 (en) | 2016-10-29 | 2018-05-02 | Miltenyi Biotec GmbH | Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens |
| SG10201912387PA (en) | 2016-11-22 | 2020-02-27 | Nat Univ Singapore | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP3601537A4 (en) | 2017-03-27 | 2021-01-13 | National University of Singapore | STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS |
| SG11201908492PA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019056174A1 (zh) * | 2017-09-19 | 2019-03-28 | 中山大学 | 一种过表达cxcr5的间质干细胞及其制备方法和用途 |
| EP3746095A4 (en) | 2018-02-01 | 2021-04-21 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| KR20200138741A (ko) | 2018-04-02 | 2020-12-10 | 내셔널 유니버시티 오브 싱가포르 | 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화 |
| WO2019222642A1 (en) * | 2018-05-18 | 2019-11-21 | Senti Biosciences, Inc. | Engineered immune cells and methods of use |
| AU2019275067A1 (en) * | 2018-05-23 | 2020-12-17 | Manysmart Therapeutics, Inc. | Bispecific T cell engager and uses thereof |
| EP3817763B1 (en) | 2018-07-03 | 2025-09-03 | SOTIO Biotech Inc. | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| CN112840019B (zh) | 2018-08-14 | 2025-07-04 | Sotio有限责任公司 | 与调节克雷布斯循环的反式代谢分子组合的嵌合抗原受体多肽及其治疗用途 |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| EP3620464A1 (en) | 2018-09-10 | 2020-03-11 | Miltenyi Biotec GmbH | Car cell having crosslinked disulfide bridge on antigen recognizing moiety |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| US20220193137A1 (en) | 2019-04-04 | 2022-06-23 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
| EP4028049A1 (en) | 2019-09-11 | 2022-07-20 | Miltenyi Biotec B.V. & Co. KG | In vitro method for transduction of t cells in the presence of malignant cells |
| EP3875478A1 (en) | 2020-03-05 | 2021-09-08 | Canvax Biotech, S.L. | Novel non-immunogenic chimeric antigen receptors and uses thereof |
| EP3878464A1 (en) | 2020-03-09 | 2021-09-15 | Miltenyi Biotec B.V. & Co. KG | Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targeting cancer cells |
| CN113583139A (zh) * | 2020-07-06 | 2021-11-02 | 上海鑫湾生物科技有限公司 | 一种嵌合受体及其应用 |
| EP4408982A1 (en) | 2021-09-27 | 2024-08-07 | SOTIO Biotech Inc. | Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
| WO2024040208A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| JPH09501055A (ja) | 1993-07-30 | 1997-02-04 | ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー | 初代リンパ球への効率的遺伝子転移 |
| JP4524181B2 (ja) * | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| WO2006105062A2 (en) * | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| US20080003225A1 (en) * | 2006-06-29 | 2008-01-03 | Henri Vie | Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors |
| WO2009016164A1 (en) * | 2007-08-01 | 2009-02-05 | Glaxo Group Limited | Novel antibodies |
| US8067339B2 (en) * | 2008-07-09 | 2011-11-29 | Merck Sharp & Dohme Corp. | Surface display of whole antibodies in eukaryotes |
| DE102009013748B4 (de) * | 2009-03-17 | 2012-01-26 | Paul-Ehrlich-Institut | Bestimmung von Interaktionen konstanter Antikörperteile mit Fc-gamma Rezeptoren |
| EP2483301A1 (en) * | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US20140072983A1 (en) * | 2010-08-10 | 2014-03-13 | Amgen Inc. | Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| MX2017003062A (es) * | 2014-09-09 | 2017-12-14 | Unum Therapeutics | Receptores quimericos y usos de los mismos en terapia inmune. |
-
2014
- 2014-10-17 WO PCT/US2014/060999 patent/WO2015058018A1/en not_active Ceased
- 2014-10-17 BR BR112016007695A patent/BR112016007695A2/pt not_active IP Right Cessation
- 2014-10-17 JP JP2016524494A patent/JP6417413B2/ja active Active
- 2014-10-17 EP EP14854582.5A patent/EP3057986B1/en active Active
- 2014-10-17 CA CA2926267A patent/CA2926267C/en active Active
- 2014-10-17 KR KR1020167012468A patent/KR102308597B1/ko active Active
- 2014-10-17 SG SG11201602979RA patent/SG11201602979RA/en unknown
- 2014-10-17 CN CN201480057323.2A patent/CN105683214B/zh active Active
- 2014-10-17 AU AU2014337195A patent/AU2014337195B2/en active Active
-
2016
- 2016-04-13 IL IL245088A patent/IL245088A0/en unknown
- 2016-04-22 ZA ZA2016/02798A patent/ZA201602798B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534717A5 (enExample) | ||
| AU2014337195B2 (en) | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors | |
| JP2017515506A5 (enExample) | ||
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| JP7382829B2 (ja) | キメラ抗原受容体を発現するｔ細胞 | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| FI4324851T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| JP2016520074A5 (enExample) | ||
| RU2017130985A (ru) | Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека | |
| JP2018506981A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| RU2016143155A (ru) | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака | |
| RU2017129455A (ru) | Сконструированные иммунные клетки с нокаутом рецептора т-клеток, снабженные химерными антигенными рецепторами, связывающимися с cd123, для лечения рецедивирующего/устойчивого острого миелоидного лейкоза или новообразования из бластных плазмоцитоидных дендритных клеток | |
| JP2017515464A5 (enExample) | ||
| JP2018029594A5 (enExample) | ||
| HRP20231542T1 (hr) | Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe | |
| IL311608A (en) | Preparations and methods for the selective elimination and replacement of hematopoietic stem cells | |
| RU2017102769A (ru) | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА | |
| JP2014533928A5 (enExample) | ||
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2018518990A5 (enExample) | ||
| JP2017537627A5 (enExample) | ||
| JP2018529327A5 (enExample) | ||
| JP2016514462A5 (enExample) | ||
| JP2017537622A5 (enExample) |